question: Several studies have compared different antithrombotic regimens in patients with COVID-19 but have not demonstrated a consistent benefit with higher doses of anticoagulants for thromboprophylaxis or empiric anticoagulation. B Introduction/Hypothesis: b Thrombotic complications occur frequently in patients infected with coronavirus disease 2019 (COVID-19) despite the use of standard prophylactic doses of anticoagulants. To date, our institution has treated over 1000 COVID-19 patients using a standardized thromboprophylaxis regimen unless the patient had a compelling reason for therapeutic anticoagulation. [Extracted from the article] Copyright of Critical Care Medicine is the property of Lippincott Williams & Wilkins and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)